Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02208362 · ClinicalTrials.gov registry record · Phase 1
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
A Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02208362 is a Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 65 participants, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02208362, a Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL Arm 1: IL13Ra2-specific CAR Tcm cells
- BIOLOGICAL Arm 2: IL13Ra2-specific CAR Tcm cells
- BIOLOGICAL Arm 3: IL13Ra2-specific CAR Tcm cells
- BIOLOGICAL Arm 4: IL13Ra2-specific CAR Tcm cells
- BIOLOGICAL Arm 5: IL13Ra2-specific CAR Tn/mem cells
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2026-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02208362
The ClinicalTrials.gov registry entry for NCT02208362 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Arm 1: IL13Ra2-specific CAR Tcm cells is the first listed.
NCT02208362 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02208362 about?
NCT02208362 is a clinical study titled "Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma". This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells ...
What is the current status of trial NCT02208362?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2015-05-18. Estimated completion is 2026-06-08.
What conditions does trial NCT02208362 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma, Recurrent WHO Grade II Glioma, Refractory Glioblastoma.
What interventions are being tested in trial NCT02208362?
The interventions under investigation include: Arm 1: IL13Ra2-specific CAR Tcm cells (BIOLOGICAL), Arm 2: IL13Ra2-specific CAR Tcm cells (BIOLOGICAL), Arm 3: IL13Ra2-specific CAR Tcm cells (BIOLOGICAL), Arm 4: IL13Ra2-specific CAR Tcm cells (BIOLOGICAL), Arm 5: IL13Ra2-specific CAR Tn/mem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02208362?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02208362 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.